https://en.bioecon.ru/niches/cmo-cdmo/Recent content in Cmo-Cdmo on BioeconHugoen-USMon, 27 Jul 2026 10:55:47 +0700https://en.bioecon.ru/technology/rna-editing-adar-therapeutics/Thu, 23 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/rna-editing-adar-therapeutics/Engineered oligonucleotides that recruit the cell’s endogenous ADAR enzymes to rewrite a pathogenic adenosine to inosine on disease transcripts — a reversible, titratable alternative to DNA editing now in clinical validation, with Wave’s WVE-006 (AATD, RestorAATion-2) the lead asset and ProQR’s Axiomer platform delivering the first clinical proof of mechanism.https://en.bioecon.ru/technology/chemoenzymatic-api-synthesis/Mon, 20 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/chemoenzymatic-api-synthesis/Engineered-enzyme steps (transaminases, ketoreductases, lipases) substituted into small-molecule API routes to replace metal-catalysed or multi-step chemical sequences — anchored by Codexis’s CodeEvolver platform (the Merck sitagliptin transaminase case) in the US, Almac’s biocatalysis CDMO in the UK, Lonza’s HPAPI/biocatalysis toolkit in Switzerland, and Asymchem and WuXi AppTec’s biocatalysis-enabled CDMO platforms in China.https://en.bioecon.ru/technology/biosynthetic-steroids/Sat, 11 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/biosynthetic-steroids/Corticosteroid and reproductive-hormone APIs made by mycobacterial fermentation of phytosterol into AD/ADD/9-OHAD precursors, then biocatalytic and semi-synthetic finishing — a globally-offshored manufacturing tier anchored by Olon, Farmabios and Gadea in Europe, Tianjin Tianyao in China, Symbiotec in India and Asymchem’s biocatalysis CDMO.https://en.bioecon.ru/technology/bispecific-antibodies/Sat, 11 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/bispecific-antibodies/Engineered antibodies that bind two (or more) antigens on one molecule — most powerfully a CD3 arm that recruits the patient’s own T cells to a tumour cell — delivered off-the-shelf as approved drugs across lymphoma and myeloma by Roche, Janssen, Regeneron, AbbVie/Genmab and BeiGene.https://en.bioecon.ru/technology/car-t-cell-therapy/Sat, 11 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/car-t-cell-therapy/A patient’s own T cells are collected, engineered with a chimeric antigen receptor (CAR) using a lentiviral vector, expanded and re-infused to kill cancer — an approved one-time living-drug class spanning CD19 lymphoma/leukemia and BCMA multiple myeloma, now advancing toward off-the-shelf allogeneic products.https://en.bioecon.ru/technology/nucleic-acid-therapeutics/Sat, 11 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/nucleic-acid-therapeutics/Short synthetic oligonucleotides — siRNA and antisense — bind a target messenger RNA to silence or reprogram a disease gene, enabled by GalNAc liver targeting and sugar/backbone chemistries, with multiple approved drugs across rare, neurological and cardiometabolic disease.https://en.bioecon.ru/technology/protacs/Sat, 11 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/protacs/Bifunctional small molecules that recruit an E3 ubiquitin ligase to a disease protein, tagging it for proteasomal destruction — an event-driven, catalytic drug modality approaching its first approval with Arvinas’s estrogen-receptor degrader vepdegestrant, and a deep pipeline across IRAK4, IKZF and BTK targets.https://en.bioecon.ru/technology/stem-cell-therapy-autoimmune/Sat, 11 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/stem-cell-therapy-autoimmune/Living mesenchymal stromal cells (MSC) or regulatory T cells (Treg) are infused to re-tolerise the immune system in autoimmune and inflammatory disease — an approved-asset class led by Mesoblast’s Ryoncil for steroid-refractory GVHD and TiGenix’s Alofisel for Crohn’s fistula, with a deeper engineered-Treg pipeline for lupus, arthritis and aplastic anemia.https://en.bioecon.ru/technology/tcr-therapy/Sat, 11 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/tcr-therapy/Patient T cells are engineered with a high-affinity T-cell receptor (TCR) that recognises a peptide-MHC complex inside a solid-tumour cell — an approved one-time therapy reaching tumour targets CAR-T cannot, led by Adaptimmune’s Tecelra and Immunocore’s Kimmtrak, with a deeper pipeline advancing MAGE-A4, NY-ESO-1, gp100 and PRAME targets.https://en.bioecon.ru/technology/process-validation-qualification-cro/Mon, 06 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/process-validation-qualification-cro/CRO-delivered three-stage process validation and IQ/OQ/PQ qualification of biopharma equipment — media fills, cleaning validation, CSV and viral clearance under FDA/EudraLex Annex 1 cGMP.https://en.bioecon.ru/technology/bioproduction-cdmo-cmo/Sun, 28 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/bioproduction-cdmo-cmo/Contract development and manufacturing organizations providing specialized infrastructure for advanced biopharmaceuticals.https://en.bioecon.ru/technology/fill-finish-aseptic-biomanufacturing/Sun, 28 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/fill-finish-aseptic-biomanufacturing/High-precision sterile filling of advanced biological drugs into final delivery formats using isolated robotic environments.https://en.bioecon.ru/technology/biologics/Thu, 18 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/biologics/Biologics — monoclonal antibodies, ADCs, CAR-T and gene therapy — are the largest and fastest-growing drug class, built on a reproducible cell-line platform at 2–10 g/L titers.https://en.bioecon.ru/technology/mrna-platforms-lnp-delivery/Thu, 18 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/mrna-platforms-lnp-delivery/Synthetic mRNA in lipid nanoparticles (60–100 nm) turns the cell into a bioreactor — from a vaccine platform to personalised cancer immunotherapy and in-vivo protein expression.https://en.bioecon.ru/technology/single-use-bioprocessing/Thu, 18 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/single-use-bioprocessing/Disposable bioreactors, bags and tubing plus modular factories (KUBio — 12–18 months vs 5–7 years) cut capex and cross-contamination, making biomanufacturing flexible and multi-product.